Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Sign Up to like & getrecommendations! Published in 2017 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2017.09.011
Abstract: BACKGROUND AND AIMS Low-density lipoprotein (LDL) apheresis has been used to treat refractory hyperlipidemia such as familial hypercholesterolemia (FH). Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor used in clinical settings, can reduce LDL… read more here.
Keywords: ldl apheresis; density lipoprotein; low density; apheresis ... See more keywords